Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-14
2006-03-14
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S317000, C514S323000, C546S208000, C546S212000, C546S224000, C546S226000
Reexamination Certificate
active
07012084
ABSTRACT:
Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
REFERENCES:
patent: 5576290 (1996-11-01), Hadley
patent: 6051555 (2000-04-01), Hadley
patent: 6166037 (2000-12-01), Budhu et al.
patent: 6350760 (2002-02-01), Bakshi et al.
patent: 6500844 (2002-12-01), Finke et al.
patent: 6511994 (2003-01-01), Kim et al.
patent: WO 99/64002 (1999-12-01), None
patent: WO 00/74649 (2000-12-01), None
patent: WO 00/76512 (2000-12-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 01/91752 (2001-12-01), None
patent: WO 02/068387 (2002-09-01), None
patent: WO 02/068388 (2002-09-01), None
Tsubouchi et al. “Preparation of 2,3-dihydro . . . ” CA 140:357387 (2004).
Lendaris et al. “Reach through claims . . . ” Intellectual property update, vo. 4, No. 5, (2004).
Baker Botts “Reach through claims” Attorneys practice profile new and events (2002).
Wessells et al., J. of Urlolgy, vol. 160(2), (1998), pp. 389-393, “Synthetic melanotropic peptide initiates erections in men with pyschogenic erectile dysfunction . . . ”.
Giraudo et al., Brain Research, vol. 809 (1998), pp. 302-306, “Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands”.
Carpino, Exp. Opin. Ther. Patents (2000), vol. 10(6), pp. 819-831, “Patent focus on new anti-obesity agents: Sep. 1999—Feb. 2000”.
Chaki et al., Exp. Opin. Ther. Patents (2001), vol. 11 (11), pp. 1677-1692, “Recent advances in feeding suppressing agents: Potential therapeutic strategy for the treatment of obesity”.
Wessells et al., Urology (2000), vol. 56, pp. 641-646, “Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction”.
Dorr et al., Life Science, vol. 58 (1996), pp. 1777-1784, “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study”.
Moreland et al., Life Sciences, vol. 62 (1998), pp. 309-318, “Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells”.
Gingell et al., Exp. Opin. Ther. Patents (1999), vol. 9(12), pp. 1689-1696, “Emerging pharamcological therapies for erectile dysfunction”.
Dinsmore et al., BMJ, vol. 318 (1999), pp. 387-390, “ABC of sexual health: Erectile dysfunction”.
Chen et al., Cell, vol. 91 (1997), pp. 789-798, “Exocrine gland dysfunction in MC5-R-deficient mice: . . . ”.
Kask et al., Biochem. & Biophys. Res. Comm., vol. 245 (1998), pp. 90-93, “Selective antagonist for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats”.
Huszar et al., Cell, vol. 88 (1997), pp. 131-141, “Targeted disruption of the melanocortin-4 receptor results in obesity in mice”.
Pertwee, Exp. Opin. Invest. Drugs, vol. 9(7), (2000), pp. 1553-1571, “Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug didcovery and development”.
Wieland et al., Exp. Opin. Invest. Drugs, vol. 9(6) (2000), pp. 1327-1346, “The role of NPY in metabolic homeostasis: Implications for obesity therapy”.
Proietto et al., Exp. Opin. Invest. Drugs, vol. 9(6), (2000), pp. 1317-1326, “Novel anti-obesity drugs”.
Fukuyama et al., Tetrahedron Lett. (1997), vol. 38, No. 33, pp. 5831-5834, “2,4-Dinitrobenzenesulfonamides: A simple and practical method for the preparation of a variety of secondary amines and diamines”.
Imai et al., Database STN No. 108:150205, Chem. Pharm. Bull., vol. 35(7), (1987), pp. 2646-2655, “Highly regioselective synthesis of trisubstituted pyrrolidines by 1,3-cycloaddition”.
Getting et al., Drug News Perspect, vol. 13(1), (2000), “MC3-R as a novel target for antiinflammatory therapy”.
Tomlinson et al., Database STN No. 135:166844 (2001).
Yoram et al., Current Opinion in Urology, vol. 7 (1997), pp. 349-353, “Oral pharmacotherapy in erectile dysfunction”.
Peptides: Frontiers of Peptide Science, Fifteenth American Peptide Symposium, Jun. 14-19, 1997 (Nashville, TN).
Heaton et al., Int;l J. of Impotence Research, vol. 9 (1997), pp. 115-121, “A therapeutic taxonomy of treatments for erectile dysfunction: An evolutionary imperative”.
Graul, Drug News & Perspectives, vol. 9(9) (1996), pp. 572-575, “Latest findings on the diagnosis and treatment of erectile dysfunction”.
Corcos et al., Society for Neuroscience, vol. 23 (1997), Abstract 267.9, “HP 228 is a potent agonists of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats”.
Ho et al., J. Org. Chem. (1995), vol. 60, pp. 2271-2273, “Lithium-initiated imide formation. A simple method for N-acylation of 2-oxazolidinones and bornane-2,10-sultam”.
Rohr et al., Heterocycles (1996), vol. 43, pp. 2131-2138, “Synthesis of 2-or/and 6-methylated analogues of isoguvacine (1,2,3,6-eterahydropyridine-4carboxylic acid) a GABAA Agonist”.
Trost et al., J. Am. Chem. Soc. (1979), vol. 101, p. 6429-6432, “New conjunctive reagents. 2-acetoxymethyl-3-allyltrimethylsilane for methylenecyclopentane . . . ”.
Olofson et al., J. Org. Chem., vol. 49 (1984), pp. 2081-2082, “A new reagents for the selective, high yield N-dealkylation of tertiary amines . . . ”.
Goulet Mark T.
Nargund Ravi P.
Ujjainwalla Feroze
Walsh Thomas F.
Warner Daniel
Brown Baerbel R.
Chang Celia
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
Acylated piperidine derivatives as melanocortin-4 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylated piperidine derivatives as melanocortin-4 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated piperidine derivatives as melanocortin-4 receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3525459